ADC Linker-Drug Structure for Stable Circulation and Toxin Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates face challenges with linker stability in blood circulation, inefficient toxin release within cells, and high polymer content due to hydrophobic structures, leading to toxicity and reduced efficacy.
Innovation Solution
A novel linker structure comprising a maleimide or cyclooctyne fragment linked with 1-5 amino acids or derivatives, enabling enzymatic hydrolysis for toxin release and reducing hydrophobicity, thus stabilizing in blood and efficiently releasing cytotoxins within cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a conventional linker structure is used in antibody-drug conjugates, then the conjugate can be formed, but the linker is unstable in blood circulation and causes high polymer content
Solution Approach 1:
The patent changes the chemical parameters of the linker by incorporating maleimide or cyclooctyne fragments with specific amino acid sequences (1-5 amino acids). This chemical parameter modification enables the linker to achieve both blood circulation stability and efficient intracellular disintegration, resolving the contradiction between stability and polymer content.
Solution Approach 2:
The patent creates a composite linker structure combining maleimide/cyclooctyne fragments with amino acid sequences. This composite design integrates the stability benefits of the chemical fragment with the controlled disintegration properties of the amino acid sequence, simultaneously addressing stability and polymer content issues.
2Reliability
If a linker structure is designed for stability in blood circulation, then circulation stability improves, but toxin release efficiency within cells deteriorates
Solution Approach 1:
The patent introduces dynamic behavior to the linker through its dual-character design: stable in blood circulation but prone to enzymatic hydrolysis within cells. The amino acid sequence portion (1-5 amino acids) provides enzymatic lability while the maleimide/cyclooctyne fragment provides circulatory stability, enabling the linker to transition from stable to labile based on environment.
Solution Approach 2:
The patent applies local quality by making different portions of the linker have different properties: the maleimide/cyclooctyne fragment provides stability in the blood environment, while the amino acid sequence portion provides enzymatic lability in the intracellular environment. This local differentiation resolves the contradiction between circulatory stability and toxin release efficiency.
3Ease of manufacture
If hydrophobic structures are used in the linker, then conjugation is facilitated, but polymer content increases and efficacy decreases
Solution Approach 1:
The patent changes the hydrophobicity parameter of the linker by using maleimide or cyclooctyne fragments combined with amino acid sequences. This parameter modification maintains conjugation feasibility while reducing hydrophobicity to prevent polymer formation, thereby preserving efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel linker structure enhances stability in blood circulation, facilitates rapid toxin release within cells, and reduces polymer content, improving the efficacy and safety of antibody-drug conjugates.
Implementation Method 1
enabling enzymatic hydrolysis for toxin release
Data Source
AI summary
A linker-drug conjugate, an antibody-drug conjugate, and a preparation method therefor and the use thereof. The linker-drug conjugate has a structure as shown in formula I, i.e., M-X-D (formula I), wherein M is a chemical structure comprising a maleimide (m) fragment or a cyclooctyne fragment, X is a linker fragment composed of 1-5 amino acids or derivatives thereof, and D is a cytotoxin. The linker-drug conjugate can release Payload by means of an enzymatic hydrolysis reaction in the case of removal of hydrophobic structure PAB, which can not only reduce the hydrophobicity of the Linker-Drug and reduce the content of a polymer produced in the preparation of ADC, but also can exhibit the corresponding cell killing activity.